FREE WEBINAR: Motivational Interviewing – Strategic Patient Engagement and Reflective Listening

This will be a rebroadcasting of the recorded webinar with LIVE audience question and answer.

The workshop engages participants using principles of motivational interviewing in the teaching methodology to build participants’ motivation to use and familiarity with the technique of motivational interviewing in clinical practice. Real play and other practical exercises will give participants the experience to implement the motivational interviewing approach immediately into their practice. Participants will practice informal coding of an interaction followed by review and discussion to learn how to identify factors that facilitate the motivational interview, and how to gauge success by learning to listen for change talk.


Expert Guest:

Dr. Brian Hurley, MD, MBA, DFASAM

Director of Addiction Medicine, Los Angeles County Department of Health Services

Brian Hurley, MD, MBA, DFASAM is an addiction physician and the Director of Addiction Medicine for the Los Angeles County Department of Health Services. As Director-at-Large, Brian currently serves as a board member of ASAM and gives presentations around the world regarding addiction medicine. He co-chairs the Los Angeles County Department of Health Services’ Substance Use Disorders Workgroup and the SafeMedLA Medications for Addiction Treatment Action Team, and is the Clinical Director of the Treatment Starts Here program through the Center for Clinical Innovation, focused on increasing the delivery of medications for addiction treatment in California’s community health centers. He is a senior researcher at the Friends Research Institute and is a primary investigator on a Tobacco Related Disease Prevention Program-funded project integrating smoking cessation services into community mental health centers and patient-centered medical homes and is the grant lead for three Medications for Addiction Treatment Access Points projects funded by the Sierra Health Foundation supporting access to medications for addiction treatment across Los Angeles County. He is also a co-investigator for several Rand Corporation projects evaluating the integration of substance use disorder treatment within community mental health and Federally Qualified Health Center settings. He also serves on the American Board of Psychiatry and Neurology’s Addiction Psychiatry Examination Writing Committee. Brian completed the Robert Wood Johnson Foundation Clinical Scholars Program at the University of California, Los Angeles (UCLA) and is an alumnus of the Massachusetts General Hospital and McLean Hospital Psychiatry Residency Training Program and the New York University Addiction Psychiatry Fellowship. Additionally, he has served in various roles for the Massachusetts Society of Addiction Medicine, New York Society of Addiction Medicine, and California Society of Addiction Medicine.

FREE WEBINAR & Q&A: So You Want To Be An Addiction Doc?

This will be a rebroadcasting of the recorded webinar with LIVE audience question and answer. In the setting of the opioid epidemic, there has been a call for enhanced and expanded medical education in substance use disorders. As the number of addiction medicine physicians completing training grows, so too do the multiple career pathways within the field. From inpatient and outpatient settings to private, public, and academic domains, a newly trained fellow or medical trainee can explore a diverse number of career options. Many fellows are engaged primarily in academic environments and are not exposed to the variety of career trajectories in the field. This session seeks to assist those who are early in their career who are either interested in or committed to addiction medicine.


Expert Guests:

Dr. Kinna Thakarar, DO, MPH

Assistant Professor of Medicine, Maine Medical Center

Dr. Kinna Thakarar is an Assistant Professor of Medicine at Maine Medical Center/Tufts University School of Medicine in Portland, Maine. She is board-certified in internal medicine, infectious diseases, and addiction medicine and has a special interest in health services research related to the ID/ substance use disorder syndemic. Dr. Thakarar is currently an affiliated investigator at the Center for Outcomes Research and Evaluation in Maine and is the PI of a pilot study supported by grant U54 GM115516 from the National Institutes of Health for the Northern New England Clinical and Translational Research network, titled “Rural Harm Reduction Access and Regional Trends Among People Hospitalized with Injection Drug Use-Associated Infections.” She completed ID fellowship and additional addiction medicine training at Boston Medical Center.


Dr. Shonali Saha, MD, FASAM

CEO and Practice Owner, Whole and Healthy You Addiction Medicine Services

Shonali Saha, MD is a board-certified internal and addiction medicine specialist. She completed fellowships in both addiction and adolescent medicine at Johns Hopkins School of Medicine. She completed her residency program at Cambridge Health Alliance of Harvard Medical School.

Dr. Saha began working in the field of substance abuse in 1996 with women mandated to residential drug treatment. She currently treats substance use disorders in adolescents, adults, and families in her own private practice. She also educates medical students, residents, and faculty on addiction medicine as an adjunct assistant professor at Emory School of Medicine and as a preceptor for physician assistant students at Mercer University.

As an active member of The Georgia Society of Addiction Medicine and a former member of The American Society of Addiction Medicine legislative committee, she is an advocate for the improvement and expansion of addiction medicine services locally and nationally.

Dr. Saha is not only a doctor, but also a certified yoga instructor. She teaches her patients breathing and other stress reduction techniques to provide evidence based treatment.

J. Deanna Wilson, MD, MPH

Assistant Professor of Medicine and Pediatrics, University of Pittsburgh

Dr. Deanna Wilson is an Assistant Professor of Medicine and Pediatrics at the University of Pittsburgh School of Medicine. She received her MD from Yale University School of Medicine and trained in internal medicine and pediatrics at the Johns Hopkins University School of Medicine. She completed additional subspecialty training in both adolescent and addiction medicine also at Johns Hopkins. She currently sees patients at UPMC’s Center for Opioid Recovery, a Pennsylvania Center of Excellence. She provides inpatient addiction medicine consultation to patients hospitalized at UPMC Presbyterian Hospital and is Medical Director for an outpatient substance use treatment clinic providing care for patients with HIV and substance use disorder. She has expertise in integrating harm reduction, substance use treatment, and primary care into clinical practice. Her current research interests are in using claims data to examine trajectories of opioid use in adolescents following first opioid exposure and also in the design and evaluation of interventions to engage and retain hospitalized young adults who inject drugs into substance use treatment.

Twitter Chat: Emergency Medicine Management of Severe Alcohol Withdrawal

Join us on Twitter @TreatmentWeek on Tuesday, October 20th as Lewis Nelson, MD shares his expertise on alcohol withdrawal management in the hospital setting.

Expert Guests:

Lorenzo Leggio, M.D., Ph.D.

Dr. Lorenzo Leggio is a Senior Investigator (Clinical) at the National Institutes of Health Intramural Research Program (NIH IRP) and serves as the Chief of the Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, a joint NIDA and NIAAA laboratory, and is the upcoming Chief of the new NIDA IRP Translational Addiction Medicine Branch. Dr. Leggio received his M.D. and Ph.D. from the Catholic University of Rome and ‘Agostino Gemelli’ hospital, where he also completed residency and received Board Certification in Internal Medicine. He also received a Masters in ‘Alcohol-related diseases and problems’ from the University of Florence. He was a visiting research associate, then postdoctoral research associate in Psychiatry and Human Behavior at Brown University, Providence, RI. In 2010, Dr. Leggio joined the faculty of the Brown University Medical School as Assistant Professor and Core Faculty at the Brown University Center for Alcohol and Addiction Studies (CAAS). Dr. Leggio’s clinical research has been primarily focused on the treatment of alcohol and substance use disorders, with a special emphasis on the role of neuroendocrine as well as GABAergic pathways; and on the medical consequences of alcohol use disorder, with a special emphasis on alcohol-associated liver disease. As a Principal Investigator at Brown University, Dr. Leggio received extramural research funding from NIAAA and NIDA, as well as from the European Foundation for Alcohol Research, Brown University CAAS, ABMRF/The Foundation for Alcohol Research, and the Brain & Behavior Research Foundation (formerly NARSAD). In 2012, Dr. Leggio joined the NIAAA and NIDA Intramural Research Programs (IRPs) as a joint Tenure-Track Clinical Investigator. He was awarded NIH tenure through the Central Tenure Committee and promoted to Senior Investigator (Clinical) in 2018 – two years early before his tenure-track clinical appointment was completed. Dr. Leggio also serves as Senior Medical Advisor to the NIAAA Director, a NIH Senior Attending Medical Staff, the Associate Director for Clinical Research for the NIDA IRP Medication Development Program and Faculty Member of the NIH Center on Compulsive Behaviors. Additionally, he is a Professor (Adjunct) at Brown University, Johns Hopkins University and Georgetown University. Dr. Leggio’s lab has pioneered clinical research on the role of neuroendocrine signaling in alcohol- and drug-seeking behaviors via preclinical and human laboratory studies. He has authored or co-authored over 170 peer-reviewed manuscripts and has served as a regular reviewer for many journals, reviewer for NIH study sections and other U.S. and international funding agencies and member of an FDA Advisory Board. He currently serves on the editorial board of several addiction-related journals and is a member of the Advisory Council of the Peter G. Dodge Foundation. Dr. Leggio has served as Chair (Medical/Clinical) of the 2016 Research Society on Alcoholism (RSA) Program Committee, is a member of the American College of Neuropsychopharmacology (ACNP) and is also Founder and Chair of the Psychoneuroendocrinology Scientific Interest Group within the NIH IRP. Among other awards, he received the 2008 European Society for Biomedical Research on Alcoholism (ESBRA) Nordmann Award, the 2015 NIAAA Clinical Service Award, the 2016 NIAAA Mentoring Award, the 2016 RSA Early Career Investigator Award and the 2018 NIAAA Scientific Achievement Award. In 2018, Dr. Leggio was presented with the ACNP Eva King Killam Award on the basis of outstanding translational research contributions to neuropsychopharmacology.

Falk Lohoff, M.D.

Dr. Falk Lohoff serves as the Chief of the Section on Clinical Genomics and Experimental Therapeutics (CGET). He received his medical degree from Humboldt University of Berlin in 2002, and completed residency training in psychiatry and a fellowship in neuropsychopharmacology at the University of Pennsylvania. He is board certified in Psychiatry since 2007. He was Assistant Professor of Psychiatry at the University of Pennsylvania from 2007-2014, after which he joined the NIH intramural program as a Lasker Clinical Research Scholar. Dr. Lohoff has worked on clinical trials in mood and anxiety disorders and has also been involved in direct patient care as the attending at the University of Pennsylvania. His research is focused on translational medicine and spans areas of molecular genetics, epigenetics, imaging-genetics, pharmacogenetics and clinical experimental trials.




FREE WEBINAR: The ASAM Alcohol Withdrawal Management Webinar Series – Pharmacotherapy

The webinar follows the ASAM Alcohol Withdrawal Management Fundamentals webinar, which intends to aid clinicians in their clinical decision making and management of patients experiencing alcohol withdrawal syndrome, as written in The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.

Appropriate pharmacotherapy for alcohol withdrawal is a balance of alleviating symptoms and normalizing signs of AWS while preventing the adverse effects associated with the medications being administered. This webinar will provide an overview of the recommendations around the appropriate use of pharmacotherapy for patients with AWS.


Expert Guest:

Michael Weaver


Michael Weaver, MD, DFASAM is a Professor in the Department of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addictions (CNRA) at the McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth). He received his M.D. degree from Northeast Ohio Medical University, and completed Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University (VCU) Health System, and he is Board-certified in Internal Medicine through the American Board of Internal Medicine and certified in Addiction Medicine through the American Board of Preventive Medicine. Dr. Weaver is the Sub-Board Chair for Addiction Medicine on the American Board of Preventive Medicine, and also serves as the Chair of the Examination Committee for certification in Addiction Medicine. He has been a member of ASAM for over 20 years and currently serves as a member of the Publications Council and the Annual Conference Program Planning Committee. He is currently involved in patient care, medical education, and research. Dr. Weaver sees patients in the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston. He has extensive experience teaching about addiction to medical students, residents, and community professionals at all levels. He has been involved in multiple research projects, and currently is collaborating with other researchers in the CNRA on studies involving cocaine, methamphetamine, marijuana, and electronic cigarettes. Dr. Weaver has multiple publications in the field of addiction medicine, including the book “Addiction Treatment” published by Carlat Publishing in 2017.

National Addiction Treatment Week Inspires Medical Professionals to Treat Addiction and Save Lives

(Rockville, MD) October 19, 2020 – Today marks the beginning of National Addiction Treatment Week, October 19-25, 2020. The week, started in 2017, raises awareness that addiction is a disease, evidence-based treatments are available, and recovery is possible. There is a critical gap between the number of patients who need addiction treatment and qualified medical professionals available to treat patients using evidence-based approaches. During this dedicated week, the partners and promotional supporters of National Addiction Treatment Week join its host, the American Society of Addiction Medicine (ASAM), to encourage medical professionals to learn more about addiction and treatment.

To save lives, patients with addiction need increased access to treatment. Expanding the number of medical professionals who are qualified to treat addiction with evidence-based care is one important way to accomplish this goal. According to SAMHSA, in 2019, 7.8 percent of people aged 12 or older (or 21.6 million people) needed substance use treatment in the past year. Of these 21.6 million, 4.2 million received treatment in that time period, with only 2.6 million receiving it at a specialty treatment facility.¹

This year, the week’s focus will be on providing clinicians and providers who work in a variety of medical settings and specialties with essential tools and resources needed to treat the disease. Physicians, board-certified in addiction medicine, and clinicians who treat addiction daily will inspire other medical professionals to join them by learning more about evidence-based treatment.

Engaging events of the week include Twitter chats with experts from ASAM, NIAAA, and NIDAMED about emergency medicine management of severe alcohol withdrawal and treating adolescents with addiction, respectively, and free insightful webinars on motivational interviewing, different career path options in addiction medicine, and alcohol withdrawal management. Throughout the week, clinicians and providers who already treat addiction will be sharing their experiences on social media.  Participate in the week by following @TreatmentWeek on Twitter and using #treatmentweek in your posts. Together, we can help more people receive evidence-based treatment and improve patient outcomes.

Learn more by visiting


Media Contact:

Christine Merrifield



¹ Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from

Twitter Chat: Adolescents and Addiction w/ NIDA/Marla Kushner, DO

The week is starting strong with a Twitter chat on treating addiction and adolescents with Marla Kushner, DO and NIDAMED science experts as panelists. (12:30 pm ET)
Join the conversation on our Twitter page, @TreatmentWeek!

Who is Marla Kushner?


Dr. Marla Kushner graduated from the Michigan State University College of Osteopathic Medicine. She completed her Family Medicine residency at Botsford General Hospital in Farmington Hills, Michigan and completed an Adolescent / Young Adult Medicine Fellowship at Chicago Osteopathic Hospital and Rush Presbyterian-St Luke’s Hospital in Chicago.

After her fellowship Dr. Kushner began working with adolescent substance abuse facilities in the Chicago area and received certification in Addiction Medicine from the American Society of Addiction Medicine.  She is a distinguished fellow of ASAM and a Diplomate in the American Board of Addiction Medicine.  Dr. Kushner received her fellowship in the American College of Osteopathic Family Physicians in March 2013 and is currently the Medical Director for New Hope Recovery Center in Chicago, The ART program at Insight Behavioral Health in Chicago, and two high school-based health centers in Chicago.  She is on the board of directors for the American Osteopathic Academy of Addiction Medicine.

Dr. Marla Kushner is actively involved in training medical students and residents carrying on her father’s legacy to ensure that new doctors have the same commitment and focus on family medicine and understand the specific issues facing patients with substance use disorders.

Dr. Kushner has been in private practice in the Lincoln Park neighborhood of Chicago for over 20 years.  She also lives in Chicago and is a actively involved in the community including volunteering as the team doctor for a local Chicago Public School as well as supporting a range of health care related and community focused organizations.


What is NIDAMED?

NIDAMED is the Physicians’ Outreach Initiative that was launched by The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, on April 20, 2009. NIDAMED’s mission is to develop science-based resources for health professionals and those in training about screening, addressing, and treating addiction. Research shows that screening, brief intervention, and referral to treatment, by clinicians in general medical settings, can promote significant reductions in alcohol and tobacco use. A growing body of literature also suggests potential reductions in illegal and nonmedical prescription drug use. NIDAMED tools, including an online screening tool and quick reference guide, are designed to fit into today’s busy clinical practices. NIDAMED enables physicians to be the first line of defense against substance abuse and addiction and to increase awareness of the likely impact of substance abuse on a patient’s overall health.



National Addiction Treatment Week Highlights the Critical Need for the Medical Community to Treat Addiction

(Rockville, MD) October 21, 2019 – Each year, National Addiction Treatment Week (NATW) raises awareness that addiction is a disease, evidence-based treatments are available, and recovery is possible.  This year, October 21-October 27, the week will highlight the critical need for clinicians to enter the field of addiction medicine. Clinicians trained in addiction are essential to fill the treatment gap between patients who need evidence-based addiction treatment and the insufficient number of clinicians qualified to treat addiction. Along with its supportive partners, the American Society of Addiction Medicine (ASAM) will be hosting the week with a dedicated twitter handle @TreatmentWeek and using #TreatmentWeek to build important conversations on social media.

More clinicians trained in addiction are needed to overcome the addiction epidemic overwhelming the United States today. In 2018, approximately 20.3 million people aged 12 or older had a substance use disorder (SUD) related to their use of alcohol or illicit drugs in the past year. 1 More people died from a drug overdose than from car accidents in 2017, 2,3 and nearly 88,000 people die from alcohol-related causes each year.4 Only about 17% of those diagnosed with substance use disorder received the treatment they need.5 In 2018, an estimated 2 million Americans were addicted to opioids, yet only about 400,000 people received treatment at a specialty facility.6

“National Addiction Treatment Week amplifies the crucial message that when patients are treated appropriately by certified addiction medicine specialists, we can save lives and improve treatment outcomes.  The medical community must be at the forefront of communities proclaiming that addiction is a chronic brain disease, not a moral failure, and as such must be treated with evidence-based, research verified care.” said Paul H. Earley, MD, DFASAM, president of ASAM. “To overcome the health crisis, we need to expand the number of medical professionals who understand the complexities of the disease and are trained to treat addiction. Only then will we see real progress.”

We are proud to stand with our dedicated National Addiction Treatment Week partners: Advocates for Opioid Recovery, the American Medical Association, the American Osteopathic Academy of Addiction Medicine, Beyond Definition, MI Cares, National Association of Addiction Treatment Providers, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Drug Abuse/NIDAMED (NIDA), and Office of National Drug Control Policy.

Join the engaging events of the week which include Twitter chats with ASAM and NIAAA on alcohol use disorder and NIDA experts on adolescents and addiction; a Facebook rebroadcast of a compelling conversation between David and Nic Sheff, from Beautiful Boy, and adolescent addiction medicine specialist, Dr. Marc Fishman; and inspiring social media posts from addiction medicine specialists throughout the week.  Together, we can help more people receive evidence-based treatment and improve patient outcomes.

Learn more by visiting